Bat T cells responses to SARS-CoV-2
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Project Summary Bats are reservoir hosts of several viruses that cause significant disease burden in humans. In nearly all of these virus-host relationships, the bats show no signs of disease and typically clear infections within a few weeks. Some have postulated that bats have “disease tolerance” that accounts for their ability to host these viruses. Although innate immunity of bat cells in vitro has been widely studied, virtually nothing is known about their adaptive immune responses to these viruses. This project will focus on cytotoxic T cell (CTL) responses of Jamaican fruit bats experimentally infected with SARS-CoV-2, the causative agent of COVID-19. We previously showed that Jamaican fruit bats have low susceptibility to SARS-CoV-2, with no evidence of infection in their lungs. However, we have overcome this limitation by using an adenovirus vector for in vivo transduction of bat lung cells with human ACE2, which subsequently leads to a robust infection of the lungs but without meaningful disease. Using this model, we previously determined that CD4+ T cells from infected bats can be identified by flow cytometry and we will extend these findings with CD8+ CTL studies. This approach will use autologous fibroblasts from wing punches generated in advance to provide MHC class I-matched antigen presenting cells (APC) prior to infection of bats with SARS-CoV-2. The APCs will then be cultured in vitro with CD8+ splenocytes from infected donor bats and peptide pools of SARS-CoV-2 spike and nucleocapsid antigens to activate antigen- specific CTLs. The CTLs will then be used for single-cell RNA sequencing analysis to determine their transcriptomic profiles in response to SARS-CoV-2 antigenic stimulation. Additionally we will deplete Jamaican fruit bats of CD8+ CTLs using a monoclonal antibody that we have developed and challenge the bats to determine the in vivo role of CTLs during SARS-CoV-2 infection. This may lead to disease, which would show that, at least, immune tolerance may not be a mechanism that explains why bats can harbor these viruses without disease. Collectively, these studies will be the first to examine cytotoxic T cell responses in bats and will fill important knowledge gaps about bat adaptive immune responses to viruses.
Grant Summary
Bat T cells responses to SARS-CoV-2 is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $45K for university, nonprofit, healthcare org. Applications are due 2029-06-10 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $45K
2029-06-10
- 1Confirm your organization is eligible for Bat T cells responses to SARS-CoV-2 from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Bat T cells responses to SARS-CoV-2: Frequently Asked Questions
Who is eligible for the Bat T cells responses to SARS-CoV-2?
Bat T cells responses to SARS-CoV-2 is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Bat T cells responses to SARS-CoV-2 provide?
Bat T cells responses to SARS-CoV-2 provides up to $45K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Bat T cells responses to SARS-CoV-2 deadline?
Applications for Bat T cells responses to SARS-CoV-2 are due 2029-06-10 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Bat T cells responses to SARS-CoV-2?
To apply for Bat T cells responses to SARS-CoV-2, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.